NEW

UVDI-360 Room Sanitizer Inactivates SARS-CoV-2 at 12 Feet Distance in 5 Minutes

UltraViolet Devices Inc. (UVDI) has announced that its UVDI-360 Room Sanitizer achieved greater than 99.99%, or 4log10, inactivation of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in 5 minutes at a distance of 12 feet (3.65 meters).

oneSOURCE Creates Free Resource Page with Up-to-Date COVID-19 Vaccine Information

Today, oneSOURCE, an RLDatix company and leading healthcare management solution, announced a new COVID-19 vaccine resource page to assist healthcare professionals during the initial administration phases of the vaccine.

STERIS to Acquire Cantel Medical

STERIS plc and Cantel Medical Corp. announced that STERIS has signed a definitive agreement to acquire Cantel, through a U.S. subsidiary. Cantel is a global provider of infection prevention products and services primarily to endoscopy and dental Customers.

NEC Releases ‘WISE VISION Endoscopy’ in Europe and Japan

NEC Corporation has announced the development of “WISE VISION Endoscopy,” an AI diagnosis-support medical device software for colonoscopies, which is being released in Japan and is expected to soon be available in Europe.

Minerva Surgical Launches Uterine Care Kit

Minerva Surgical announced today the launch of a complete suite of minimally invasive devices and website to support health care practitioners in treating Abnormal Uterine Bleeding (AUB). One-third of outpatient visits to the gynecologist are for AUB, and AUB accounts for more than 70% of all gynecologic consults in the perimenopausal and post-menopausal years[1]. This common condition often results in a hysterectomy due to benign causes if not treated.

Hysterectomy is the second most common surgery performed on reproductive-age women in the U.S., after cesarean section. Nearly 68% of the 400,000 hysterectomies performed each year are due to benign conditions that involve abnormal uterine bleeding, uterine fibroids and endometriosis[2].

The conservatively estimated annual costs of AUB were approximately $1 billion direct costs to women and $12 billion indirect costs to the community[1].

“AUB holds women hostage. Their personal and professional quality of life suffers significantly, and the financial burden is crushing,” said Dave Clapper, president & CEO, Minerva Surgical. “Our best-in-class devices are a leap forward in treatment, but we also commit to elevate awareness of AUB in our communities. We are excited to do our part to eliminate this horrible condition that too often results in unnecessary hysterectomies.”

Minerva Surgical, is comprised of a newly minted suite of minimally invasive tools: the Minerva Endometrial Ablation System, the fastest growing endometrial ablation product, Symphion, the all-in-one tissue removal system that transforms the way physicians remove uterine fibroids, Genesys HTA Endometrial Ablation System, trusted for decades by physicians desiring visualization within the uterine cavity during treatment, and the Resectr device for the removal of endometrial polyps in the medical office setting.

“Health care practitioners and their patients are benefiting from these minimally invasive devices that drive down the cost of care for AUB. And now we can help them even more with a website that serves as an on-demand tool for AUB treatment and awareness information,” said Tom Pendlebury, vice president of sales and marketing, Minerva Surgical.

Visit the new health care practitioner website at www.minervasurgical.com.

[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291434/#CR1

[2] Plotting the Downward Trend in Traditional Hysterectomy

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X